Le dernier trimestre dont nous disposons pour AgomAb Therapeutics NV

D’après le 6-K de l’entreprise.

Ce qu’a dit la direction

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”

Cité mot pour mot du communiqué, et affiché uniquement lorsque le document l’attribue à une personne nommée.

Ce que fait AgomAb Therapeutics NV

Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

La description que l’entreprise donne d’elle-même, telle qu’elle figure au bas du communiqué.